Fabry Disease Patient Serum Data for ADA and Complement Profiling

Data Sheet 1 contains serum data from a study of 39 Fabry disease patients and healthy controls. Tomas Baldwin authored the dataset, which was last updated on April 9, 2026. It likely includes quantitative measurements of antibody subclasses and complement proteins related to enzyme replacement therapy.

Use Cases

• Analyze sex-based differences in IgG4 antibody levels based on the finding of significantly higher IgG4 in Fabry males
• Correlate antibody subclass binding with complement activation based on described correlations between IgG1, IgG2, IgM, IgA1 and C1Qc
• Assess neutralizing capacity of anti-drug antibodies based on enzymatic inhibition assay results
• Evaluate cross-reactivity profiles between different enzyme replacement therapies based on IgG4 binding comparisons
• Investigate relationships between antibody levels and clinical biomarkers based on the correlation between IgG4 and lyso-Gb3

Strengths

• Includes data from 39 Fabry patients and healthy controls, providing a clinical cohort
• Quantifies multiple antibody subclasses (IgG1-4, IgM, IgA1) and complement proteins (C1Qc-C9)
• Contains results from a neutralizing capacity assay measuring enzymatic inhibition

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is 228.7 KB, indicating a very limited scope

Provenance

Source

Tomas Baldwin

Collection Method

Created via a targeted LC-MS/MS platform applied to serum samples

Freshness

Last updated 2026-04-09 04:11:12; freshness should be verified